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Abstract
Next-generation sequencing (NGS) was applied to 148 lung neuroendocrine tumours (LNETs) comprising the four
World Health Organization classification categories: 53 typical carcinoid (TCs), 35 atypical carcinoid (ACs), 27
large-cell neuroendocrine carcinomas, and 33 small-cell lung carcinomas. A discovery screen was conducted on 46
samples by the use of whole-exome sequencing and high-coverage targeted sequencing of 418 genes. Eighty-eight
recurrently mutated genes from both the discovery screen and current literature were verified in the 46 cases of
the discovery screen, and validated on additional 102 LNETs by targeted NGS; their prevalence was then evaluated
on the whole series. Thirteen of these 88 genes were also evaluated for copy number alterations (CNAs). Carcinoids
and carcinomas shared most of the altered genes but with different prevalence rates. When mutations and copy
number changes were combined, MEN1 alterations were almost exclusive to carcinoids, whereas alterations of TP53
and RB1 cell cycle regulation genes and PI3K/AKT/mTOR pathway genes were significantly enriched in carcinomas.
Conversely, mutations in chromatin-remodelling genes, including those encoding histone modifiers and members
of SWI–SNF complexes, were found at similar rates in carcinoids (45.5%) and carcinomas (55.0%), suggesting
a major role in LNET pathogenesis. One AC and one TC showed a hypermutated profile associated with a POLQ
damaging mutation. There were fewer CNAs in carcinoids than in carcinomas; however ACs showed a hybrid
pattern, whereby gains of TERT , SDHA, RICTOR, PIK3CA, MYCL and SRC were found at rates similar to those in
carcinomas, whereas the MEN1 loss rate mirrored that of TCs. Multivariate survival analysis revealed RB1 mutation
(p= 0.0005) and TERT copy gain (p= 0.016) as independent predictors of poorer prognosis. MEN1 mutation was
associated with poor prognosis in AC (p= 0.0045), whereas KMT2D mutation correlated with longer survival in
SCLC (p= 0.0022). In conclusion, molecular profiling may complement histology for better diagnostic definition
and prognostic stratification of LNETs.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Lung neuroendocrine tumours (LNETs) are subclas-
sified into four histological variants: typical carcinoid
(TC), atypical carcinoid (AC), large-cell neuroen-
docrine carcinoma (LCNEC), and small-cell lung
carcinoma (SCLC) [1]. Cytological features, neuroen-
docrine immunohistochemical markers, the number of
mitoses/2 mm2 and the presence of necrosis are the
main diagnostic criteria [1].
This four-tier histological spectrum clinically cor-
responds to a prognostic scheme whereby TCs are
low-grade tumours, with patients having a long life-
expectancy, ACs are intermediate-grade tumours with
varying clinical behaviour, and LCNECs and SCLCs are
high-grade tumours with a dismal prognosis [2–6]. The
clinical management of LNETs reflects this prognostic
categorization: TC patients are treated with surgery, AC
and LCNEC patients are treated with with multimodal
approaches involving surgery and/or systemic therapy,
and SCLC patients usually undergo systemic therapy
[7]. The 10-year overall survival rate of TC patients is
reported to be 87%, whereas the median overall survival
of patients with untreated SCLC is only 2–3 months,
reaching 1 year when they are treated [8].
A better understanding of the genomic changes
occurring in LNET is essential to identify new ther-
apeutic targets and markers for better prognostic
stratification. Previous molecular studies on LNET
[9–12] have highlighted frequent alterations in the
chromatin-remodelling genes MEN1, PSIP1 and
ARID1A in carcinoids (ACs and TCs) [9]. Conversely,
inactivating mutations in TP53 and RB1, amplification
of MYC family members and genetic alterations in
the PI3K/AKT/mTOR pathway have frequently been
observed in SCLC [9,10,12,13].
To complement these reports, we performed a direct
comparison of the four histotypes by whole-exome
sequencing (WES) and high-coverage targeted sequenc-
ing (HCTS) of 418 genes on a cohort of 46 LNETs, and




A cohort of 148 surgically treated LNETs was col-
lected from four Italian institutions (ARC-Net Research
Centre-Verona; IRCCS San Martino-Genova; Univer-
sity of Pisa; and AUO Orbassano-University of Torino),
and comprised: 53 TCs, 35 ACs, 27 LCNECs, and 33
SCLCs. The inclusion condition was a concordant diag-
nosis among five pathologists based on morphological
and immunohistochemical criteria of the World Health
Organization (WHO) classification [1]. No patient
received preoperative therapy. Samples had been frozen
for 46 cases (23 TCs, 14 ACs, five LCNECs, and four
SCLCs), and were formalin-fixed paraffin-embedded
(FFPE) for 102 cases (28 TCs, 21 ACs, 24 LCNECs,
and 29 SCLCs).
Ethics
Ethics Committee Approval (ECA) was obtained
at the four institutions: AUO Orbassano-University
of Torino, ECA no. 161/2012-prot.17751 (2 Octo-
ber 2012); ARC-Net Research Centre-Verona, ECA
no. 2173-prot.26775 (1 June 2012); IRCCS San
Martino-Genova, ECA no. 027/2016LM (16 March
2016); University of Pisa, ECA no. 1040/16 (31 March
2016).
Discovery screen on 46 LNETs by WES and HCTS
of 418 genes
Matched tumour/normal DNA available in high quan-
tity from 20 frozen LNETs (10 TCs; four ACs; three
LCNECs; and three SCLCs) was subjected to WES
with a HiSeq2000 sequencer (Illumina, Milan, Italy).
The same 20 cases and an additional 26 frozen LNETs
(13 TCs; 10 ACs; two LCNECs; and one SCLC) with
DNA available in low quantity were subjected to HCTS
of 418 genes with a customized version of the Ion
AmpliSeq Comprehensive Cancer Panel (ThermoFisher,
Milan, Italy). Mutational and copy number alteration
(CNA) analysis was performed as described in supple-
mentary material, Supplementary materials and meth-
ods, and citations therein [9,10,12–20].
Validation of mutations and CNAs in 102 LNETs
by targeted sequencing of 88 genes
Matched tumour/normal DNA from 102 FFPE LNETs
was subjected to targeted next-generation sequencing
(NGS) to validate the prevalence of somatic alterations
in 88 genes, selected as follows: 42 from the dis-
covery screen, and 46 from current LNET literature
[9,10,12,13]. To this end, we used four multigene panels
(supplementary material, Supplementary materials and
methods and Table S1).
Statistical analysis
One-way ANOVA, the Kruskal–Wallis test, Fisher’s test
with Monte Carlo simulation and Fisher’s exact test were
used as appropriate; multiple comparisons were cor-
rected according to Benjamini–Hochberg. For compar-
ison of Kaplan–Meier survival curves, the Mantel–Cox
test was used. For multivariate survival analysis, a step-
wise Cox regression with forward algorithm was used. A
p-value of <0.05 was considered to be significant. Anal-
yses were performed with Medcalc for Windows v.15.6
(MedCalc Software, Ostend, Belgium) and R v.3.2.1
with survival library v.2.38-2.
Results
The study workflow is illustrated in Figure 1. The clin-
icopathological characteristics of the 148 LNETs are
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summarized in Table 1 and detailed in supplementary
material, Table S2, with indications of the molecular
analyses performed. A discovery screen for mutations
and CNAs was performed on DNA from 46 frozen
samples, with WES on 20 cases (high-quantity DNA
samples) and HCTS of 418 genes on these and an
additional 26 (low-quantity DNA samples). An 88-gene
panel was then selected as follows: 42 genes from this
discovery screen, including 13 that showed CNAs, i.e.
BCL2, FGFR1, MEN1, MYC, MYCL, PIK3CA, RB1,
RICTOR, SDHA, SMAD4, SRC, TERT , and TP53 (panel
3 of supplementary material, Table S1), and 46 from
a literature review [9,10,12,13]. These 88 genes were
verified by targeted NGS in the discovery set, and then
assessed on a validation set of an additional 102 FFPE
LNETs. The prevalence of mutations and CNAs was
computed on the whole 148 cases cohort. The results
of the mutational analysis of 88 genes are detailed in
supplementary material, Table S3, and summarized in
Figure 2A for the 26 genes mutated in at least three
cases. Eleven of these 26 genes met the criteria for sta-
tistical analysis of prevalence among LNET histotypes
(genes altered in at least 10% of at least one histotype),
with seven genes showing a statistically significant
difference (Table 2). The results of CNA analysis of 13
genes are shown in Figure 2B and reported in Table 3.
Discovery screen by WES and HCTS of 418 genes
Mutational analysis
The 46-case discovery set was composed of two groups
based on the amount of available DNA: 20 high-quantity
DNA samples (10 TCs; four ACs; three LCNECs; and
three SCLCs) and 26 low-quantity DNA samples (13
TCs; 10 ACs; two LCNECs; and one SCLC). Each group
was analysed according to DNA availability: WES and
HCTS for high-quantity DNA samples, and HCTS for
low-quantity ones.
WES achieved an average coverage of× 94
(×75–161) in tumour samples and× 72 (×38–161)
in normal samples. One thousand three hundred and
twenty-two non-synonymous somatic mutations were
found, including 1184 missense and 88 nonsense muta-
tions, 34 frameshifts, six in-frame insertions, and 10
in-frame deletions (supplementary material, Figure
S1A and Table S4A). The mean numbers of mutations
per sample were 14.6 for TCs, 15.7 for ACs, 64.7 for
LCNECs, and 90.7 for SCLCs. One TC (no. 304) and
one AC (no. 389) emerged among carcinoids as having
a hypermutated profile, as they respectively contained
228 and 434 mutations, i.e. a gross excess of point muta-
tions relative to the same tumour type (supplementary
material, Figure S1A). These cases shared inactivating
somatic mutations of POLQ, encoding polymerase θ
(supplementary material, Table S4A), and hypermutated
profiles have been associated with mutations of genes
encoding polymerases [21,22].
HCTS of 418 genes on the 46 cases of the discovery
set yielded an average coverage of× 864 (×298–1657)
Figure 1. Flow chart of the experiments performed on 148 LNETs.
The chart shows the workflow of sequencing analysis, including
discovery screen on 46 fresh-frozen cases and validation on 102
FFPE cases.
in tumour samples and× 686 (×670–1316) in normal
samples. Mutations were identified in 36 genes, and
were 145 missense mutations, 13 nonsense mutations,
two frameshifts, five splice site alterations, and one
in-frame deletion (supplementary material, Table S4B
and Figure S1B). The mean numbers of mutations per
sample were 0.7 for TCs, 1.8 for ACs, 4.6 for LCNECs,
and 5.8 for SCLCs. One hundred and sixteen of the 1322
somatic mutations identified by WES were targetable by
HCTS, and all of them were confirmed.
In conclusion, WES and HCTS sequencing on the
discovery set of 46 cases identified 36 genes as recur-
rently mutated (i.e. in at least two cases of different
histotypes on both WES and HCTS) (Figure 1; supple-
mentary material, Table S4C).
Copy number alterations
CNA analysis of the discovery set was performed with
data from both WES on the 20 cases with high DNA
quantity and HCTS of 418 genes on the whole discov-
ery set.
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Table 1. Comparison of clinicopathological features of 148 lung neuroendocrine tumours across the four histotypes defined by the World
Health Organization classification
Clinicopathological features TC (n= 53) AC (n= 35) LCNEC (n= 27) SCLC (n= 33) p-Value*
Mean age (years)± SD 54.1± 15.3 61.2± 15.1 70.4± 7.2 66.9± 9.4 < 0.0001†
Females/males (no.) 33/20 20/15 5/22 10/23 0.0002
Smokers/non-smokers (no.) 17/13 15/11 16/6 26/1 0.0013
Missing value (no.) 23 9 5 6
Median tumour size (cm) 2.5 2.8 3.3 2.8 0.10‡
1st–3rd quartile 1.7–3.2 1.6–4.4 2.3–3.8 2.4–3.5
Missing value (no.) 0 0 1 14
Mitotic count (mean) 0.6 3.5 36.0 36.7 < 0.0001†
Range 0–1 1–7 11–79 18–130
Ki67 index (mean) 3.7 12.5 71.2 65.3 < 0.0001†
Range 1–15 2–45 20–95 40–95
pT (no.) < 0.0001
T1 35 16 8 8
T2 15 14 11 10
T3 2 5 7 3
T4 1 0 1 12
pN (no.) < 0.0001
N0 48 24 18 4
N1 4 8 3 9
N2 1 3 5 19
N3 0 0 1 1
pM (no.) < 0.0001
M0 53 34 24 22
M1 0 1 3 11
Tumour stage (no.) < 0.0001
I 46 17 11 2
II 4 15 8 4
III 3 2 5 16
IV 0 1 3 11
AC, atypical carcinoid; LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell lung cancer; SD, standard deviation; TC, typical carcinoid.
*Fisher’s exact test was used for categorical variables. Fisher’s test with Monte Carlo simulation was used for pT, pN, pM, and tumour stage. The Shapiro–Wilk test was
used to test the Gaussian distribution of continuous variables.
†aThe Kruskal–Wallis test was used for age.
‡aOne-way ANOVA on log-transformed data for tumour size.
Large structural CNA analysis, which was feasible
only for WES cases, showed frequent gains of chromo-
somes 5p (7/20; 35.0%) and 8 (5/20; 25.0%), and loss of
heterozygosity (LOH) of chromosome 3 (5/20; 25.0%)
(Figure 3A). Carcinoids showed rare CNAs. However,
three cases showed an unusually unstable genomic pro-
file: AC no. 450 and the hypermutated TC no. 304
showed alterations in several chromosomes (Figure 3A),
whereas AC no. 034 showed a copy number pattern com-
patible with chromothripsis of chromosomes 2, 11, and
20 (supplementary material, Figure S2). Six of the eight
classification criteria used to define chromothripsis [23]
are assessable by WES: five were fulfilled for chromo-
somes 2 and 11, and four for chromosome 20. Con-
versely, carcinomas had many large structural CNAs,
including copy gains at chromosomes 5p and 8, and
LOH at chromosome 13 and 17p, where RB1 and TP53,
respectively, are located.
Gene-level CNAs were investigated on the discovery
set with both WES data (Figure 3B; supplementary
material, Table S5A) and HCTS data (supplemen-
tary material, Figure S1B and Table S5B). The most
recurrent copy loss events involved one or both copies
of RB1 (TCs, 13.0%; ACs, 14.3%; LCNECs, 60.0%;
SCLCs, 50.0%) and TP53 (TCs, 8.7%; ACs, 7.1%;
LCNECs, 20.0%; SCLCs, 75.0%). Conversely, frequent
concurrent gains were observed for BRD9, CTNND2,
and TERT (TCs, 8.7%; ACs, 14.3%; LCNECs, 40.0%;
SCLCs, 75.0%). Additional frequent gains included
MYC (TCs, 4.3%; ACs, 7.1%; LCNECs, 80.0%;
SCLCs, 50.0%), SDHA (TCs, 4.3%; ACs, 7.1%;
LCNECs, 60.0%; SCLCs, 75.0%) and RICTOR (TCs,
8.7%; ACs, 14.3%; LCNECs, 40.0%; SCLCs, 50.0%).
Although a specific CNA hallmark of each histolog-
ical subtype was not apparent, the average number of
genes affected by CNA progressively increased from
TCs to SCLCs (TCs, 1.3; ACs, 2.0; LCNECs, 10.8;
SCLCs, 14.7; p< 0.0001), with ACs showing a hybrid
profile between TCs and carcinomas.
Prevalence of mutations in 148 LNETs
To validate mutations, verification was performed on
the 46 discovery set cases and an additional valida-
tion set of 102 FFPE samples (29 TCs; 21 ACs; 24
LCNECs; and 28 SCLCs) with four NGS multigene
panels (supplementary material, Table S1) designed to
target 88 genes, including 42 identified by our discov-
ery screen and 46 recurrently altered according to the
LNET literature [9,10,12,13] (Figure 1). Prevalence was
then computed on the entire cohort of 148 LNETs. The
results of mutation analysis are summarized in Table 2
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 488–500
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Figure 2. Recurrent alterations in 148 LNETs. Cases are grouped according to the four histotypes defined by the WHO classification. The
histograms on the left report the alteration frequency of each gene expressed as a percentage. Alterations are annotated by different
colours, according to their impact on the gene product. (A) The upper histogram shows the number of mutations in recurrently altered
genes for each sample. Asterisks indicate the two hypermutated cases that emerged from WES. The matrix shows 26 genes that were
mutated in at least three cases. (B) The matrix shows the copy number status of 13 genes in the whole cohort.
and Figure 2, and detailed in supplementary material,
Table S3. Overall, carcinomas had more mutations than
carcinoids. The mean number of mutations among the
four LNET subtypes was as follows: TCs, 0.8; ACs,
1.6; LCNECs, 3.0; and SCLCs, 2.9. At the single-gene
level, the most frequently altered genes were MEN1 in
carcinoids (10/88; 11.4%), particularly in ACs (20%;
p= 0.022), and TP53 in carcinomas (TCs, 9.4%; ACs,
11.4%; LCNECs, 67.0%; SCLCs, 63.6%; p= 5.4E-10).
A similar distribution was observed for KMT2D (TCs,
1.9%; ACs, 8.6%; LCNECs, 18.5%; SCLCs, 24.2%;
p= 0.0094). It is of note that mutations in SMARCA2
were exclusive to LCNECs (11.1%; p= 0.011). As pre-
viously reported [13,24], we identified sporadic KRAS
mutations in both carcinoids and carcinomas. but these
tumours were not associated with clinicopathological
features of aggressiveness.
Chromatin-remodelling genes were mutated in carci-
noids (40/88; 45.5%) and carcinomas (33/60; 55.0%) at
similar rates (p= 0.32, computed from supplementary
material, Table S3; Figure 4). Specifically, the KMT2
family of covalent histone modifiers (KMT2A, KMT2C,
and KMT2D) was mutated in 12 of 88 (13.6%) carci-
noids versus 16 of 60 (26.7%) carcinomas (p= 0.11),
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 488–500
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Table 2. Differences in mutation prevalence for 11 recurrently mutated genes among the four histotypes of 148 lung neuroendocrine
tumour (LNET) (related to Figure 2A)
Gene* TC (n= 53), no. (%) AC (n= 35), no. (%) LCNEC (n= 27), no. (%) SCLC (n= 33), no. (%) p-Value†
Adjusted
p-value‡
TP53 5 (9) 4 (11) 18 (67) 21 (64) 4.5E-11 5.4E-10
LRP1B 2 (4) 1 (3) 5 (19) 11 (33) 0.00015 0.00088
KMT2D 1 (2) 3 (9) 5 (19) 8 (24) 0.0039 0.0094
CSMD3 2 (4) 0 (0) 7 (26) 7 (21) 0.00027 0.0011
RB1 1 (2) 1 (3) 4 (15) 8 (24) 0.0015 0.0047
MEN1 3 (6) 7 (20) 1 (4) 0 (0) 0.013 0.022
PCLO 1 (2) 3 (9) 3 (11) 3 (9) 0.28 0.28
KMT2C 3 (6) 4 (11) 2 (7) 0 (0) 0.23 0.27
NOTCH2 2 (4) 2 (6) 4 (15) 1 (3) 0.27 0.28
PIK3CA 0 (0) 1 (3) 3 (11) 1 (3) 0.055 0.073
SMARCA2 0 (0) 0 (0) 3 (11) 0 (0) 0.0055 0.011
AC, atypical carcinoid; LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell lung cancer; TC, typical carcinoid.
*Eighty-eight genes were analysed; 56 of them were found to be mutated in at least one case, and are reported in supplementary material, Table 3. Genes met the
criteria for prevalence statistical analysis when mutated in at least 10% of an individual LNET histotype.
†aFisher’s exact test.
‡aCorrection for multiple comparisons according to Benjamini–Hochberg.
Table 3. Copy number alterations detected in 148 lung neuroendocrine tumours by targeted sequencing of 13 genes according to
histotype (related to Figure 2B)
TC (n= 53), no. (%) AC (n= 35), no. (%) LCNEC (n= 27), no. (%) SCLC (n= 33), no. (%)
Gene HD LOH G HD LOH G HD LOH G HD LOH G p-Value*
Adjusted†
p-value
RB1 7 (13.2) 6 (11.3) 2 (5.7) 2 (5.7) 9 (33.3) 6 (22.2) 13 (39.4) 10 (30.3) 2.7E-07 1.9E-06
TP53 2 (3.8) 8 (15.1) 2 (5.7) 8 (22.9) 11 (40.7) 14 (42.4) 0.078 0.084
TERT 3 (5.6) 15 (42.9) 5 (18.5) 17 (51.5) 1.3E-06 5.6E-06
SDHA 5 (9.4) 14 (40.0) 6 (22.2) 13 (39.4) 0.0015 0.0032
RICTOR 2 (3.8) 10 (28.6) 10 (37.0) 13 (39.4) 3.7E-05 0.00012
PIK3CA 2 (3.8) 4 (11.4) 9 (33.3) 17 (51.5) 2.9E-07 1.9E-06
MYC 7 (13.2) 4 (11.4) 6 (22.2) 8 (24.2) 0.37 0.37
MEN1 8 (15.1) 8 (22.9) 1 (3.7) 0.0061 0.011
SMAD4 2 (3.8) 1 (2.9) 3 (8.6) 8 (29.6) 1 (3.0) 2 (6.1) 0.0079 0.011
MYCL 7 (20.0) 5 (18.5) 4 (12.1) 0.0013 0.0032
SRC 4 (11.4) 3 (11.1) 3 (9.1) 0.030 0.039
FGFR1 1 (3.7) 4 (12.1) 0.0070 0.011
BCL2 2 (5.7) 3 (9.1) 0.049 0.058
AC, atypical carcinoid; G, gain; HD, homozygous deletion; LCNEC, large-cell neuroendocrine carcinoma; LOH, loss of heterozygosity; SCLC, small-cell lung cancer; TC,
typical carcinoid.
*Comparison of copy number alteration frequency among histotype by Fisher’s exact test.
†aCorrection for multiple comparisons according to Benjamini–Hochberg.
and the ARID family, involved in the SWI–SNF com-
plex (ARID1A, ARID1B, and ARID2), had mutations in
eight of 88 (9.0%) carcinoids versus six of 60 (10.0%)
carcinomas (p= 1.0). In contrast, the TP53, RB1 and
ATM cell cycle checkpoint genes showed a significantly
higher rate of mutations in carcinomas (42/60; 70.0%)
than in carcinoids (9/88; 10.2%; p< 0.0001; Figure 4).
Similarly, components of the PI3K/AKT/mTOR path-
way showed a mutation rate higher in carcinomas than
in carcinoids (11.7% versus 2.3%; p= 0.031).
Prevalence of CNAs in 148 LNET
Recurrent CNAs detected in the discovery screen were
assessed in the 102 cases of the validation set by targeted
sequencing of 13 genes (panel 3, supplementary mate-
rial, Table S1): BCL2, FGFR1, MEN1, MYC, MYCL,
PIK3CA, RB1, RICTOR, SDHA, SMAD4, SRC, TERT ,
and TP53. The prevalence of CNAs was then computed
on the entire cohort of 148 LNETs, and is illustrated in
Figure 2B and detailed in Table 3.
RB1 was the gene most frequently affected by losses
across all samples, with a different distribution between
subtypes (TCs, 24.5%; ACs, 11.4%; LCNECs, 55.6%;
SCLCs, 69.7%; p= 1.9E-06), and the highest frequency
in SCLCs was mainly attributable to homozygous dele-
tions (13/33, 39.4%). When homozygous deletions were
combined with deleterious mutations, the prevalence of
RB1 alterations in SCLCs was 64% (21/33), and when
10 cases with LOH were added, the prevalence was 91%
(30/33). TP53 was the second most frequent gene show-
ing loss of one or both copies (TCs, 18.9%; ACs, 28.6%;
LCNECs, 40.7%; SCLCs, 48.5%; p= 0.084). LOH in
MEN1 was significantly more frequent in carcinoids
than in carcinomas (TCs, 15.1%; ACs, 22.9%; LCNECs,
3.7%; SCLCs, 0%; p= 0.011).
TERT , SDHA and RICTOR had the most frequent
copy number gains (26.4%, 25.7% and 23.6% of all
cases, respectively), with significant enrichment in
carcinomas (Table 3). Gains of PIK3CA were also
frequent (21.6% of all cases), and were distributed
differently among subtypes (p= 1.9E-06) (Table 3).
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 488–500
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Figure 3. Somatic copy number alterations detected in 20 LNETs by WES. Cases are grouped according to the four histotypes defined by the
WHO classification, and arranged from the most to the least altered within each category. Asterisks indicate the two hypermutated cases
that emerged from WES. (A) Copy gain (red/yellow) or loss (cyan/blue) of large chromosomal regions. (B) Overview of genes affected by
either somatic mutation or copy number alteration. For each case, the upper panel shows somatic mutations, and the lower panel shows
copy number alterations, both annotated according to the colour panels at the bottom.
Gains involving MYC were sporadically distributed
among subtypes.
Survival analysis
Follow-up was available for 117 cases (TCs, 39; ACs,
28; LCNECs, 22; SCLCs, 28). The median survival time
was 74 months, and 39 (33%) subjects died of disease
(TCs, 0; ACs, 6; LNECs, 9; SCLCs, 24).
On univariate analysis, significant clinicopathological
predictors of poorer outcome among the whole cohort
were tumour histotype (p< 0.0001; Figure 5), tumour
stage [stage I hazard ratio (HR)= 1; stage II HR= 2.8;
stage III HR= 12.5; stage IV HR= 19.4; p< 0.0001],
age over 60 years (HR= 5.6; p< 0.0001), and male sex
(HR= 3.5; p= 0.0004). Multivariate analysis confirmed
the follwing as main predictors of unfavourable prog-
nosis: histotype (LCNEC HR= 4.7, p= 0.0057; SCLC
HR= 12.3, p< 0.0001) and tumour stage III (HR= 2.7;
p= 0.041) and IV (HR= 6.1; p= 0.0004).
To identify prognostic molecular markers in all
LNETs, we screened the following common alterations
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 488–500
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Molecular landscape of lung neuroendocrine tumours 495
Figure 4. Somatic mutations in chromatin-remodelling and cell cycle checkpoint genes for 148 LNETs. Cases are grouped according to the
four histotypes defined by the WHO classification. Micrographs illustrate a representative case for each histotype. Genes are grouped as
per molecular pathway. The histograms on the left show the mutation frequency of each gene expressed as a percentage. Mutations are
annotated according to the colour panels at the bottom.
among the three subtypes showing disease-specific mor-
tality (ACs, LCNECs, and SCLCs): KMT2D mutation,
MYC copy gain, PIK3CA copy gain, RB1 mutation, RB1
homozygous deletion, RICTOR copy gain, TERT copy
gain, TP53 mutation, and TP53 LOH. TC cases were
excluded from this analysis, given that their features
(i.e. no death of disease after long follow-up) would
have represented a confounding effect on analysis of the
impact of molecular markers on the rest of the series.
Each marker yielding a p-value of <0.2 on univariate
survival analysis (supplementary material, Table S6
and Figure S3) was tested in a multivariate model
against the significant clinicopathological predictors
of tumour stage and histotype. The final analysis con-
firmed RB1 mutation, TERT copy gain, histotype and
tumour stage as independent factors for poor prognosis
(Table 4).
We also performed a stratified univariate analysis
for mutations clustering to specific tumour histotypes,
which showed a significant association of MEN1 muta-
tion with poor prognosis in ACs (p= 0.0045), in which
MEN1 mutations were mainly confined to early-stage
tumours. Among SCLCs, KMT2D mutation was almost
exclusive to stage III tumours [five mutated of 13 stage
III (38.5%) versus one mutated of 11 stage IV (9%)], and
correlated with longer survival (p= 0.0022).
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Figure 5. Disease-specific survival according to pathological and molecular features. (A) Disease-specific survival of patients with LNET
(n= 117) is significantly affected by histology (p < 0.0001). (B, C) The presence of MEN1 mutation in ACs correlates with poor prognosis
(p = 0.0045) (B), whereas KMT2D mutation is linked to better prognosis in patients with SCLC (p = 0.0022) (C). Survival time is expressed in
months. Kaplan–Meier and log-rank statistics were used to determine levels of significance. x-Axes are trimmed for visualization purposes.
Table 4. Multivariate analysis on 117 lung neuroendocrine tumours showed mutation in RB1 and gain in TERT as independent prognostic
markers of poor prognosis
Covariate Univariate hazard ratio 95% CI Multivariate hazard ratio 95% CI p-Value*
Histotype= LCNEC 2.45 0.91–6.61 3.84 1.28–11.52 0.016
Histotype= SCLC 6.53 2.45–17.40 5.41 1.55–18.93 0.0082
Stage= III 12.47 4.88–31.88 3.90 1.40–10.87 0.0091
Stage= IV 19.45 5.60–67.49 9.14 3.18–26.29 <0.0001
RB1: mutation† 3.29 0.96–11.30 5.76 2.14–15.50 0.0005
TERT : gain† 1.55 0.80–3.02 2.55 1.19–5.44 0.016
CI, confidence interval; LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell lung cancer.
*Cox proportional-hazards regression analysis. Selection of the best model was performed with the ‘forward’ algorithm.
†aUnivariate analysis of RB1 mutation and TERT copy gain includes only atypical carcinoids, LCNECs, and SCLCs. Typical carcinoid cases were excluded from univariate
analysis of molecular alterations, given that their features (i.e. no death from disease after long follow-up) would have represented a confounding effect on analysis
of the impact of molecular markers on the rest of the series.
Discussion
Although the WHO classification defines clinically
relevant subgroups of LNET, there is still a need for
better diagnostic definition and prognostic stratifi-
cation within subtypes. Therefore, we performed a
direct comparison of molecular features of the four
LNET subtypes, which to date has been lacking, on
a cohort of 148 cases classified by five independent
pathologists according to WHO criteria [1], including
morphology, appropriate immunohistochemistry, and
proliferation rate.
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The results of our study can be summarized as fol-
lows: (1) carcinoids and carcinomas shared most of the
altered genes, but with different prevalence rates among
subtypes; (2) when mutations and copy number changes
were combined, MEN1 alterations were almost exclu-
sive to carcinoids, whereas alterations of the TP53 and
RB1 cell cycle regulation genes and PI3K/AKT/mTOR
pathway genes were significantly enriched in carcino-
mas; (3) chromatin-remodelling genes showed compa-
rably high mutation rates in carcinoids and carcinomas;
(4) rare carcinoids showed a hypermutated phenotype,
which was associated with damaging POLQ mutations;
(5) the prevalence of CNA was lower in carcinoids than
in carcinomas – however, ACs showed an intermediate
profile, with gains of several genes at rates similar to
those in carcinomas, and loss of MEN1 at a frequency
comparable to that in TCs; and (6) RB1 mutation and
TERT gain were independent unfavourable prognostic
markers in all LNET series, whereas MEN1 mutation
was associated with poor prognosis in ACs, and KMT2D
mutation was associated with longer survival in SCLCs.
No genetic alteration was exclusive to a specific
LNET subtype, but the differences between carcinoids
and carcinomas reside in the prevalence rates of the
most frequently mutated genes, with the exception
of SMARCA2, which was altered in LCNECs only
(p= 0.011). Overall, this is in line with previous reports,
and further demonstrates that the phenotypic classifi-
cation of LNETs into carcinoids (ACs and TCs) and
carcinomas (LCNECs and SCLCs) is supported by the
different molecular landscapes of these tumours
[9,12,25].
When mutations and CNAs were combined, inac-
tivating alterations of TP53 and RB1 were enriched
in carcinomas (p< 0.0001), whereas MEN1 alterations
were almost exclusive to carcinoids (p= 0.0004). How-
ever, the fact that the same gene alterations found
in carcinomas are identified in low-grade tumours at
lower prevalence rates may suggest the existence of
a progression of malignancy, with the development
of secondary high-grade neuroendocrine tumours from
pre-existing carcinoids. This has been suggested on
molecular grounds in pancreatic and thymus neuroen-
docrine tumours [26,27], reinforcing the biological rel-
evance of intratumour heterogeneity.
Chromatin-remodelling genes, which include those
encodig covalent histone modifiers and subunits of
the SWI–SNF complex, emerged from the present
study as the group of genes with the highest mutation
rate in both carcinoids (45%) and carcinomas (55%).
Fernandez-Cuesta et al reported a similar mutation fre-
quency of chromatin-remodelling genes (52%) in their
study of 44 carcinoids, including 35 TCs and nine ACs
[9]. A more recent study by Rekhtman et al reported a
78% mutation frequency of chromatin modifiers in 45
LCNECs [25]; in the same publication, the authors also
re-analysed data of 42 SCLCs from Hyman et al [28]
and Paik et al [29], and showed that 64% of SCLCs
have chromatin-remodelling gene alterations. Our direct
comparison of all subtypes complements these previous
observations, and suggests that chromatin modifiers
are major players in the pathogenesis of all LNETs.
However, their role in carcinoids may be more relevant,
as these tumours have a low mutational background,
whereas carcinomas have a high mutational background
and feature inactivation of genes involved in cell cycle
control, such as TP53 and RB1 (carcinomas versus car-
cinoids, p< 0.0001). Carcinomas are also enriched in
mutations of the oncogenic PI3K/AKT/mTOR pathway
(carcinomas versus carcinoids, p= 0.0313), a potential
therapeutic target to be investigated in prospective
trials [10].
In our mutational analysis, carcinoids showed a lower
mean number of mutations (TCs, 0.7; ACs, 1.8) than
carcinomas (LCNECs, 4.6; SCLCs, 5.8), in line with
current literature. However, two carcinoids (one TC and
one AC) showed a hypermutated phenotype, which is
defined as a gross excess of point mutations relative to
the same tumour type [30]. The total numbers of muta-
tions of these two cases were nine in the TC and 14 in
the AC. Moreover, the total numbers of mutations deter-
mined on WES were 228 for the TC and 434 for the
AC, well beyond the average mutational burden found
on WES in our carcinoids (14.9 mutations/case) and
those reported in the literature (14.0 mutations/case, as
calculated from Fernandez-Cuesta et al) [9]. Common
to these cases was the presence of inactivating muta-
tions of POLQ that could be linked to this peculiar
genomic profile. POLQ encodes DNA polymerase θ, an
enzyme implicated in DNA repair [31]: POLQ-defective
mammalian cells are susceptible to DNA double-strand
breaks, and show increased rates of homologous recom-
bination [21,32]. Interestingly, one of these cases also
showed CNAs in several chromosomes, suggestive of
defective DNA repair. The hypermutated carcinoids had
proliferation rates within the range of their respec-
tive WHO categories. Mitotic counts were TC= 1 and
AC= 6 per 2 mm2, with the WHO criteria setting being
0–1 for TC and 2–10 for AC [1]. The Ki67 prolifera-
tion index was TC= 7% and AC= 15%, which fits in the
range of their respective categories [33]. Moreover, these
cases had no clinicopathological evidence of aggressive-
ness, and both patients were disease-free at 21 months
(TC) and 17 months (AC). As this is a short follow-up
for carcinoids, we have no definitive indication as to
the clinical significance of this phenotype. A third car-
cinoid showed CNAs consistent with chromothripsis of
chromosomes 2, 11, and 20. Chromothripsis has been
recently described in a stage III atypical carcinoid of
a smoker patient [9], whereas our case was a stage IV
atypical carcinoid of a non-smoker patient.
There were fewer CNAs in carcinoids than in carci-
nomas. Within individual subtypes, losses of MEN1 in
ACs and losses of RB1 in SCLCs were the most frequent
events, in agreement with previous literature [12,34].
However, an increase in the number of CNA events
was observed from low-grade to high-grade tumours,
especially for concomitant gains of TERT , SDHA and
RICTOR located on the p-arm of chromosome 5. On
WES analysis, we observed gain of chromosome 5p,
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with SDHA and RICTOR being located at the edges
of and TERT within the altered chromosomal region.
Therefore, as the limited material available did not
allow us to perform fluorescence in situ hybridization
or WES analysis on the whole LNET series, these three
genes were included in the validation NGS panels, and
their simultaneous CNAs were assessed as a surrogate
of 5p gains. Gain of 5p has already been reported as
a common event in all lung cancer types, suggesting
that genes located on this chromosomal arm might be
involved in development of all lung tumour types [35].
Of those genes, RICTOR encodes for a protein of the
mTORC2 complex, whose amplification has recently
been demonstrated to define the sensitivity of lung
cancer cell lines to mTORC1/2 inhibitors [36]. When
mutational and CNA analysis were combined, ACs were
shown to be hybrid tumours sharing molecular features
of both low-grade (TC) and high-grade (LCNEC and
SCLC) tumours. In particular, ACs had frequencies
of MEN1 losses and mutations comparable to those in
TCs, and their overall mutational burden was 2.6 times
higher than that in TCs and 2.9 times lower than that
in carcinomas. However, they shared with carcinomas
a similar prevalence of copy gains in several genes,
including the chromosome 5p genes TERT , SDHA, and
RICTOR, but also SRC and MYCL.
Survival analysis highlighted the prognostic rele-
vance of RB1 and TERT regardless of subtype, whereas
KMT2D was prognostically relevant for SCLCs, and
MEN1 for ACs. Mutation of RB1 and copy gain of TERT
are reported herein for the first time as independent pre-
dictors of poor prognosis in patients with LNETs. A
correlation between alterations of these genes and poor
prognosis has been observed for RB1 in non-small-cell
lung cancers [37] and anaplastic astrocytoma [38], and
increased mRNA expression of TERT was previously
reported as a poor prognostic marker in breast [39] and
lung [40] cancers. We report for the first time that muta-
tions affecting KMT2D in SCLC patients correlate with
longer survival, as previously observed for pancreatic
adenocarcinoma [41]. The value of MEN1 mutation as
an unfavourable prognostic predictor in patients with
AC is in line with our previous finding of a significant
association between inactivation of MEN1 and poor
prognosis [34].
The fact that our discovery set included a higher num-
ber of carcinoids than of carcinomas was attributable
to the following: (1) the availability of high-quality
DNA from adequate amounts of frozen material – this
is obtainable from surgically treated tumours, and
SCLCs and LCNECs are rarely surgically resected; and
(2) permission to use tissue for research, which is
limited by the need to preserve material for clinical
use. This could be considered a weakness of the study,
as it might have led to a low-grade-driven validation
gene list. However, to overcome this potential bias, we
increased the gene list derived from the discovery screen
with genes identified as altered in the current LNET
literature [9,10,12,13].
In conclusion, our comprehensive molecular study
encompassing all four histological variants of LNET
indicated that a featured molecular portrait stands
behind the commonly adopted histological classi-
fication, with a mixture of genetic similarities and
differences among the four WHO LNET histotypes.
This was mirrored by survival analysis, in which alter-
ations in RB1 and TERT were common to all subtypes,
and showed an independent poor prognostic role in all
LNETs, whereas mutations of MEN1 and KMT2D were
specifically enriched and showed a prognostic impact
in ACs and SCLCs, respectively. Other genes that we
found to be altered in LNETs are, instead, amenable to
therapeutic targeting, including alterations leading to
PI3K/AKT/mTOR pathway activation, namely PIK3CA
mutations and copy gains of PIK3CA and RICTOR [10].
Our data suggest that molecular profiling may comple-
ment histology to provide better diagnostic definition
and prognostic stratification of LNETs that would be
helpful for their clinical management.
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